Table 2.
Outcome data in the whole population and subgroups. MO: molecularly oriented.
| All Patients (n = 103) | MO (n = 17) | No-MO (n = 86) | p-Value | |
|---|---|---|---|---|
| Time to best response | 7 ± 1 months | 9 ± 4 months | 6 ± 1 months | 0.47 |
| Response | ||||
| VGPR | 28% (n = 30) | 53% (n = 9) | 24% (n= 21) | 0.053 |
| PR | 19% (n = 20) | 12% (n = 2) | 21% (n = 18) | |
| MR | 11% (n = 11) | 0% (n = 0) | 13% (n= 11) | |
| SD | 21% (n = 22) | 12% (n = 2) | 23% (n = 20) | |
| PD | 20% (n = 21) | 24% (n = 4) | 20% (n= 17) | |
| Δ MC (median) | −34% | −91% | −30% | 0.33 |
| PFS (median) | 7 months | 9 months | 6 months | 0.88 |
| OS (median) | 28 months | 26 months | 28 months | 0.98 |
| Deaths | 52% (n = 54) | 47% (n = 8) | 53% (n = 46) | 0.23 |
| MM-related | 85% (prop: 45/54) | 88% (prop: 7/8) | 85% (prop: 39/46) |
No-MO: not molecularly oriented, NS: no significant difference, VGPR: very good partial response—>90% reduction in serum M-protein, PR: partial response—>50% reduction in serum M-protein, MR: minimal response—M protein reduction between 25% and 50%, SD: stable disease, PD: progressive disease—M protein augmentation >25%, Δ MC: variation in monoclonal component, PFS: progression-free survival, OS overall survival, MM: multiple myeloma.